NO313199B1 - Krystallinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat - Google Patents

Krystallinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat Download PDF

Info

Publication number
NO313199B1
NO313199B1 NO19953564A NO953564A NO313199B1 NO 313199 B1 NO313199 B1 NO 313199B1 NO 19953564 A NO19953564 A NO 19953564A NO 953564 A NO953564 A NO 953564A NO 313199 B1 NO313199 B1 NO 313199B1
Authority
NO
Norway
Prior art keywords
crystalline
acid
oil
preparation
free
Prior art date
Application number
NO19953564A
Other languages
English (en)
Norwegian (no)
Other versions
NO953564D0 (no
NO953564L (no
Inventor
Michael S Bergren
Gregory E Hardee
Kenneth Paul Shephard
Robert Shih-Liang Chao
Jeffrey L Havens
Michael J Dunn
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO953564D0 publication Critical patent/NO953564D0/no
Publication of NO953564L publication Critical patent/NO953564L/no
Publication of NO313199B1 publication Critical patent/NO313199B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19953564A 1993-03-12 1995-09-11 Krystallinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat NO313199B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3329193A 1993-03-12 1993-03-12
PCT/US1994/001862 WO1994020505A1 (en) 1993-03-12 1994-03-07 Crystalline ceftiofur free acid

Publications (3)

Publication Number Publication Date
NO953564D0 NO953564D0 (no) 1995-09-11
NO953564L NO953564L (no) 1995-11-07
NO313199B1 true NO313199B1 (no) 2002-08-26

Family

ID=21869579

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19953564A NO313199B1 (no) 1993-03-12 1995-09-11 Krystallinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat
NO2005025C NO2005025I2 (no) 1993-03-12 2005-11-18 krystallinsk ceftiofur i form av den frie syre

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005025C NO2005025I2 (no) 1993-03-12 2005-11-18 krystallinsk ceftiofur i form av den frie syre

Country Status (31)

Country Link
US (1) US5721359A (en:Method)
EP (1) EP0690864B1 (en:Method)
JP (1) JP3852946B2 (en:Method)
KR (1) KR100296810B1 (en:Method)
CN (1) CN1055090C (en:Method)
AT (1) ATE202109T1 (en:Method)
AU (1) AU694419B2 (en:Method)
BR (1) BR1101034A (en:Method)
CA (1) CA2155322C (en:Method)
CZ (1) CZ289332B6 (en:Method)
DE (2) DE122005000055I2 (en:Method)
DK (1) DK0690864T3 (en:Method)
ES (1) ES2157254T3 (en:Method)
FI (1) FI120307B (en:Method)
FR (1) FR05C0045I2 (en:Method)
GR (1) GR3036514T3 (en:Method)
HU (1) HU222244B1 (en:Method)
IL (1) IL108910A (en:Method)
LU (1) LU91206I2 (en:Method)
LV (1) LV12889B (en:Method)
NL (1) NL300208I2 (en:Method)
NO (2) NO313199B1 (en:Method)
NZ (1) NZ263002A (en:Method)
PL (1) PL184611B1 (en:Method)
PT (1) PT690864E (en:Method)
RU (1) RU2136685C1 (en:Method)
SI (1) SI0690864T1 (en:Method)
SK (1) SK283674B6 (en:Method)
TW (1) TW267170B (en:Method)
WO (1) WO1994020505A1 (en:Method)
ZA (1) ZA941586B (en:Method)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
MXPA03002055A (es) * 2000-09-12 2004-12-13 Upjohn Co Composicion farmaceutica con excipiente modificado.
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
CA2453182A1 (en) * 2001-07-10 2003-01-23 Meredith L. Greene Crystalline thiazine oxazolidinones
JP4159988B2 (ja) * 2001-08-15 2008-10-01 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｎ−［２−（ジエチルアミノ）エチル］−５−［（５−フルオロ−１，２−ジヒドロ−２−オキソ−３ｈ−インドール−３−イリデン）メチル］−２，４−ジメチル−１ｈ−ピロール−３−カルボキシアミドのリンゴ酸塩を含む結晶、その製法およびその組成物
KR20040097187A (ko) 2002-03-21 2004-11-17 파마시아 앤드 업존 캄파니 동물의 귀로의 주사가능한 항생제의 투여 방법
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US20040115822A1 (en) * 2002-09-12 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US20040115837A1 (en) * 2002-11-27 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
SI1606293T1 (sl) * 2003-03-27 2009-10-31 Basilea Pharmaceutica Ag Cefalosporin v kristalni obliki
KR101156406B1 (ko) 2004-03-25 2012-06-13 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US8470809B2 (en) * 2005-10-12 2013-06-25 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US8212024B2 (en) * 2005-10-12 2012-07-03 Orchid Chemicals & Pharmaceuticals Ltd. Crystalline sodium salt of cephalosporin antibiotic
DK2195293T3 (da) 2007-08-22 2014-02-03 Astrazeneca Ab Cyclopropylamidderivater
EP2303026B1 (en) 2008-06-17 2020-09-09 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
WO2010020871A2 (en) * 2008-08-22 2010-02-25 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
JP5685193B2 (ja) * 2008-11-19 2015-03-18 メリアル リミテッド セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2536685B1 (en) * 2010-02-18 2015-04-08 AstraZeneca AB Processes for making cyclopropyl amide derivatives and intermediates associated therewith
EP2536701A4 (en) * 2010-02-18 2014-05-07 Astrazeneca Ab SOLID FORMS WITH A CYCLOPROPYLAMID DERIVATIVE
EP2705044A1 (en) * 2011-05-02 2014-03-12 Zoetis Llc Novel cephalosporins useful as antibacterial agents
JP6272224B2 (ja) 2011-07-20 2018-01-31 ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍ Ｙｏｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 疎水性セラゲニン化合物、及びそれを組み込む装置
CA2852989C (en) 2011-09-13 2021-06-29 Brigham Young University Compositions for treating bone diseases and broken bones
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
US9161942B2 (en) 2011-09-13 2015-10-20 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
BR112014015144B1 (pt) 2011-12-21 2018-03-27 Brigham Young University Composição aquosa para cuidado oral, uso de um composto esteroide catiônico e método não- terapêutico de redução de compostos voláteis de enxofre
CN102584855B (zh) * 2012-02-16 2014-06-25 青岛科技大学 一种改进的头孢噻呋的制备方法
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
EP2908826A1 (en) 2012-10-17 2015-08-26 Brigham Young University Treatment and prevention of mastitis
JP6310396B2 (ja) * 2012-12-03 2018-04-11 株式会社カネカ 還元型補酵素ｑ１０誘導体およびその製造方法
EP2941253B1 (en) 2013-01-07 2021-08-11 Brigham Young University Cationic steroid antimicrobial agents for use in treating cancer
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
JP6518230B2 (ja) 2013-03-15 2019-05-22 ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍ Ｙｏｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 炎症、自己免疫疾患、および疼痛を治療する方法
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
RU2546675C2 (ru) * 2013-04-11 2015-04-10 Федеральное казённое предприятие "Государственный научно-исследовательский институт химических продуктов" (ФКП "ГосНИИХП") Способ определения степени кристалличности составов на основе дифениламина
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
EP3360858B1 (en) * 2013-09-05 2020-04-29 Mitsubishi Tanabe Pharma Corporation Process for producing an aminopyrrolidine derivative
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
HRP20201343T1 (hr) * 2014-10-21 2020-11-27 Ariad Pharmaceuticals, Inc. Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
WO2016172553A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
WO2016172543A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
KR101753842B1 (ko) * 2015-05-12 2017-07-04 한국화학연구원 불화퀴놀론계 항생제를 담지한 서방형 제제 및 이의 제조방법
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
CN106543203B (zh) * 2015-09-18 2019-07-02 瑞普（天津）生物药业有限公司 一种长效头孢噻呋自由酸晶体的制备方法
ES2834049T3 (es) * 2016-01-22 2021-06-16 Sandoz Ag Bisclorhidrato de eravaciclina cristalino
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
KR101898282B1 (ko) * 2016-05-24 2018-09-13 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
MX389964B (es) 2016-07-07 2025-03-19 Cyclerion Therapeutics Inc Formas sólidas de un estimulador de guanilato ciclasa soluble (sgc).
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US11186556B1 (en) * 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
UA119735C2 (uk) 2018-12-20 2019-07-25 Анатолій Семенович Редер Фармацевтична сполука, спосіб її отримання та застосування як лікарського засобу
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
CN117229296A (zh) * 2023-09-14 2023-12-15 广东温氏大华农生物科技有限公司 一种头孢噻呋酸晶体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207933B (de) * 1962-12-26 1965-12-30 American Home Prod Verfahren zur Herstellung von kristallwasser-freiem D-alpha-Aminobenzylpenicillin
US3489750A (en) * 1967-09-05 1970-01-13 Bristol Myers Co 7-amino-cephalosporanic and decephalosporanic acid derivatives
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4400503A (en) * 1981-10-30 1983-08-23 Eli Lilly And Company Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid
DE3313818A1 (de) * 1983-04-16 1984-10-18 Hoechst Ag, 6230 Frankfurt Neue kristallmodifikation von ceftazidim
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
IT1181672B (it) * 1984-10-25 1987-09-30 Upjohn Co Cefalosporina alogenidrato cristallino
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions
EP0233255B1 (en) * 1985-08-12 1996-05-29 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
IT1214587B (it) * 1986-12-23 1990-01-18 Giovanni Bonfanti Metodo per la produzione diprodotti cristallini puri.
ES2032543T3 (es) * 1987-02-02 1993-02-16 Eli Lilly And Company Procedimiento mejorado de preparacion de un antibiotico.
WO1989000852A1 (en) * 1987-07-29 1989-02-09 The Upjohn Company Controlled release of antibiotic salts from an implant
US5134137A (en) * 1987-11-10 1992-07-28 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes

Also Published As

Publication number Publication date
CZ289332B6 (cs) 2002-01-16
ATE202109T1 (de) 2001-06-15
ES2157254T3 (es) 2001-08-16
HU222244B1 (hu) 2003-05-28
LV12889B (lv) 2002-12-20
DE69427469D1 (en) 2001-07-19
AU694419B2 (en) 1998-07-23
NZ263002A (en) 1996-12-20
DK0690864T3 (da) 2001-09-17
CA2155322C (en) 2000-02-29
DE122005000055I2 (de) 2008-06-05
HUT73781A (en) 1996-09-30
WO1994020505A1 (en) 1994-09-15
AU6351094A (en) 1994-09-26
JPH08507519A (ja) 1996-08-13
FR05C0045I1 (en:Method) 2006-01-06
NL300208I1 (nl) 2006-02-01
IL108910A0 (en) 1994-06-24
NO2005025I2 (no) 2010-11-22
US5721359A (en) 1998-02-24
CN1119016A (zh) 1996-03-20
SI0690864T1 (en) 2001-10-31
SK283674B6 (sk) 2003-11-04
NO953564D0 (no) 1995-09-11
FI954250A0 (fi) 1995-09-11
HU9501960D0 (en) 1995-09-28
CN1055090C (zh) 2000-08-02
DE69427469T2 (de) 2001-10-31
IL108910A (en) 1999-10-28
ZA941586B (en) 1995-09-07
JP3852946B2 (ja) 2006-12-06
PL184611B1 (pl) 2002-11-29
SK111495A3 (en) 1995-12-06
NO2005025I1 (no) 2005-12-05
EP0690864A1 (en) 1996-01-10
NL300208I2 (nl) 2006-05-01
KR100296810B1 (ko) 2001-10-24
GR3036514T3 (en) 2001-12-31
PL310556A1 (en) 1995-12-27
DE122005000055I1 (de) 2006-02-23
PT690864E (pt) 2001-11-30
LU91206I2 (fr) 2006-05-30
FI954250L (fi) 1995-09-11
FI120307B (fi) 2009-09-15
TW267170B (en:Method) 1996-01-01
BR1101034A (pt) 2002-04-30
FR05C0045I2 (en:Method) 2007-08-03
CA2155322A1 (en) 1994-09-15
NO953564L (no) 1995-11-07
RU2136685C1 (ru) 1999-09-10
EP0690864B1 (en) 2001-06-13
CZ9502290A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
NO313199B1 (no) Krystallinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat
US4241057A (en) Antibiotic compositions
HU184835B (en) Process for preparing crystallic pentahydrate of cefem-carboxylic acid derivatives
PL172835B1 (pl) Chlorowodorek kwasu 7- ß -[(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3 -cefemo-4-karboksylowego oraz sposób jego wytwarzania, krystaliczny wodzian chlorowodorku kwasu 7- ß -(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3-ce- femo-4-karboksylowego oraz sposób jego wytwarzania PL PL PL PL PL
EP2870163A1 (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
JPS6145626B2 (en:Method)
US20050209211A1 (en) Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
CA1248088A (en) Crystalline cephalosporin hydrohalid salts
WO2007042917A1 (en) Crystalline sodium salt of cephalosporin antibiotic
CS195746B2 (en) Process for preparing crystalline methanolate of natrium salt of cephamandole
JP2723088B2 (ja) セファロスポリン化合物の新規な結晶
KR0137211B1 (ko) 세팔로스포린유도체의 결정성 2염산염 및 그 제조법
AU672056B2 (en) Cephalosporin salts and process for the preparation thereof
JPH01199977A (ja) セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物
JPH0692970A (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
MXPA06010489A (en) Trihemihydrate, anhydrate and hydrate forms of cefdinir
JPS6052751B2 (ja) 新規な結晶形を有するセフアレキシン１水和物
CS195747B2 (cs) Způsob výroby krystalické bezvodé sodné soli cefamandolu

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: NAXCEL VET. 100 MG/ML INJEKSJON, SUSPENSJON TIL GRIS; NAT. REG. NO/DATE: EU/2/05/053/001/NO 20050519; FIRST REG. NO/DATE: EU , EU/2/05/053/001 20050519

Spc suppl protection certif: 2005025

Filing date: 20051118

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: NAXCEL VET. 100 MG/ML INJEKSJON, SUSPENSJON TIL GRIS; NAT. REG. NO/DATE: EU/2/05/053/001/NO 20050519; FIRST REG. NO/DATE: EU , EU/2/05/053/001 20050519

Spc suppl protection certif: 2005025

Filing date: 20051118

Extension date: 20190307

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ZOETIS P&U LLC, US

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2005025

Effective date: 20190402